Global Soliris Intravenous Market Size By Type (Plasma Exchange, Plasma Infusion), By Application (PNH, AHUS), By Region, And Segment Forecasts, 2023 to 2032

The Global Soliris Intravenous Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 6.9 billion by 2031, growing at a CAGR of 6.0% during the forecast period from 2023 to 2031. Soliris (eculizumab), a monoclonal antibody delivered intravenously, is primarily used to treat rare and life-threatening blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). Increasing prevalence of these ultra-rare diseases, enhanced diagnosis rates, and favorable regulatory frameworks are key growth drivers for this market.

Drivers

Rising Incidence of Rare Blood Disorders

The growing number of diagnosed cases of rare hematological and neurological conditions like PNH and aHUS is fueling demand for advanced biologics like Soliris. Increased awareness and improvements in diagnostic capabilities have resulted in higher detection rates, positively impacting market growth.

Favorable Reimbursement Policies

Many healthcare systems across North America and Europe have implemented reimbursement frameworks that cover high-cost orphan drugs, significantly reducing the financial burden on patients and driving adoption rates.

Expansion of Clinical Indications

Regulatory approvals expanding Soliris’s use beyond PNH and aHUS to conditions like neuromyelitis optica spectrum disorder (NMOSD) and gMG are broadening its application scope, increasing demand globally.

Restraints

High Treatment Costs

Soliris remains one of the most expensive drugs worldwide, with annual treatment costs often exceeding hundreds of thousands of dollars per patient. The high cost limits access, particularly in developing regions, and presents a key restraint on market growth.

Patent Expiry and Biosimilar Threat

The impending expiration of Soliris patents is paving the way for biosimilar competition. While this could reduce costs, it also introduces market fragmentation and pricing pressure.

Opportunity

Emerging Markets and Orphan Drug Incentives

Untapped potential in emerging markets such as Brazil, India, and China, coupled with government incentives for orphan drug development, offers significant expansion opportunities. Collaborations with local healthcare providers and favorable pricing strategies could unlock new growth avenues.

Innovations in Intravenous Delivery Systems

Ongoing innovations in IV drug administration—such as shorter infusion times and home-based infusion solutions—are enhancing patient experience and compliance, supporting broader adoption of Soliris therapy.

Market by System Type Insights

By system type, the Standard Soliris IV Infusion segment accounted for the largest share in 2023. This form remains the primary delivery method due to its efficacy and established usage in hospitals and specialty clinics. However, the Rapid Infusion Protocol segment is gaining traction owing to reduced infusion durations, improving patient convenience and clinic throughput.

Market by End-use Insights

Hospitals dominated the end-use segment in 2023, contributing over 60% of total revenue. Hospitals remain the primary treatment centers for complex conditions requiring IV biologic therapies. The Specialty Clinics segment is expected to grow rapidly, propelled by increased decentralization of rare disease treatments and demand for personalized care environments.

Market by Regional Insights

North America led the global market in 2023, supported by strong healthcare infrastructure, favorable insurance coverage, and high disease awareness. Europe followed closely, benefiting from well-established orphan drug pathways and early access programs. Asia-Pacific is projected to be the fastest-growing region due to increasing healthcare expenditure, growing awareness of rare diseases, and supportive regulatory reforms.

Competitive Scenario

Key players in the Global Soliris Intravenous Market include:

Alexion Pharmaceuticals (AstraZeneca)

Roche Holding AG

Novartis AG

Amgen Inc.

Samsung Bioepis

Chugai Pharmaceutical

Apellis Pharmaceuticals

These companies are actively investing in expanding clinical indications, forming strategic alliances, and developing biosimilars to strengthen market presence. Notably:

In 2024, Alexion Pharmaceuticals began trials for a next-generation Soliris formulation aimed at reducing infusion frequency.

Apellis Pharmaceuticals gained regulatory approval in 2023 for a competing C3 inhibitor with IV delivery, introducing competitive dynamics.

Scope of Work – Global Soliris Intravenous Market

Key Market Developments

2023: Alexion Pharmaceuticals launched a home-infusion program for Soliris to enhance treatment accessibility.

2024: Roche announced plans to enter the IV rare disease biologics segment through strategic acquisitions.

2025: Novartis filed regulatory applications for a biosimilar version of eculizumab in Europe and Asia-Pacific.

FAQs

1) What is the current market size of the Global Soliris Intravenous Market?

The market was valued at USD 4.1 billion in 2023.

2) What is the major growth driver of the Global Soliris Intravenous Market?

Rising incidence of rare blood and neurological disorders and expansion of approved indications.

3) Which is the largest region during the forecast period in the Global Soliris Intravenous Market?

North America is expected to remain the largest market regionally.

4) Which segment accounted for the largest market share in Global Soliris Intravenous Market?

The Standard Soliris IV Infusion segment held the largest share by system type in 2023.

5) Who are the key market players in the Global Soliris Intravenous Market?

Major players include Alexion Pharmaceuticals (AstraZeneca), Roche, Novartis, Amgen, and Apellis Pharmaceuticals.